Detailed Information on Publication Record
2020
The manifestation of oral mucositis in COVID-19 patients: A case-series
RIAD, Abanoub, Islam KASSEM, Mai BADRAH and Miloslav KLUGARBasic information
Original name
The manifestation of oral mucositis in COVID-19 patients: A case-series
Authors
RIAD, Abanoub (818 Egypt, guarantor, belonging to the institution), Islam KASSEM (818 Egypt), Mai BADRAH (818 Egypt) and Miloslav KLUGAR (203 Czech Republic, belonging to the institution)
Edition
Dermatologic Therapy, Hoboken, Wiley, 2020, 1396-0296
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30216 Dermatology and venereal diseases
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.851
RIV identification code
RIV/00216224:14110/20:00116797
Organization unit
Faculty of Medicine
UT WoS
000587315600001
Keywords in English
Oral Mucositis; COVID-19
Změněno: 13/1/2021 13:39, Mgr. Tereza Miškechová
Abstract
V originále
We have read with great interest the correspondence of Kahraman et al (2020) on the emergence of oral mucosal changes adjacent to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; hereby we demonstrate the characteristics of 13 laboratoryconfirmed coronavirus disease (COVID-19) patients with oral mucositis according to the CARE guidelines. The referenced patients sought care at our department from April to August 2020 due to generalized pain and soreness within the oral cavity related mainly to nonkeratinized mucosa without a specific cause (Table 1). All included patients had previously undergone polymerase chain reaction (PCR) testing for SARS-CoV-2, which confirmed their infection with a mean cycle threshold (Ct) value of 18.46 ± 3.8 (12-26). Their mean age was 51.08 ± 8.79 (34-62) years old, and eight of them (62.5%) were females. Regarding their COVID-19 symptoms, two patients (15.4%) had persistent fever, four (30.8%) had ageusia, and two (15.4%) had anosmia. The majority of them (69.2%) had a mild course of SARS-CoV-2 infection and were prescribed paracetamol (PCM); contrarily, four patients experienced a moderate course of infection—two patients (15.4%) were prescribed chloroquine and other two (15.4%) were prescribed dexamethasone.